PDE5A inhibitor treatment of persistent pulmonary hypertension after mechanical circulatory support.

Ryan J. Tedford, Anna R. Hemnes, Stuart D. Russell, Ilan S Wittstein, Mobusher Mahmud, Ari L. Zaiman, Stephen Mathai, David Ross Thiemann, Paul M Hassoun, Reda E. Girgis, Jonathan B Orens, Ashish S. Shah, David Yuh, John V. Conte, Hunter C. Champion

Research output: Contribution to journalArticle

Abstract

Pulmonary hypertension (PH) secondary to left heart failure portends a poor prognosis and is a relative contraindication to heart transplantation at many centers. We tested the hypothesis that when PH persists after adequate left ventricle unloading via recent left ventricular assist device (LVAD) therapy, phosphodiesterase type 5A inhibition would decrease PH in this population. We performed an open-label clinical trial using control patients not receiving therapy. Between 1999 and 2007, 138 consecutive patients undergoing cardiac transplantation evaluation with advanced left ventricular dysfunction, an elevated pulmonary capillary wedge pressure, and PH (defined by a pulmonary vascular resistance (PVR) >3 Woods Units), were treated with LVAD therapy. Fifty-eight of these patients reduced their pulmonary capillary wedge pressure to a value

Original languageEnglish (US)
Pages (from-to)213-219
Number of pages7
JournalCirculation: Heart Failure
Volume1
Issue number4
StatePublished - Nov 2008
Externally publishedYes

Fingerprint

Pulmonary Hypertension
Pulmonary Wedge Pressure
Heart-Assist Devices
Heart Transplantation
Type 5 Cyclic Nucleotide Phosphodiesterases
Left Ventricular Dysfunction
Therapeutics
Vascular Resistance
Heart Ventricles
Heart Failure
Clinical Trials
Population

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Tedford, R. J., Hemnes, A. R., Russell, S. D., Wittstein, I. S., Mahmud, M., Zaiman, A. L., ... Champion, H. C. (2008). PDE5A inhibitor treatment of persistent pulmonary hypertension after mechanical circulatory support. Circulation: Heart Failure, 1(4), 213-219.

PDE5A inhibitor treatment of persistent pulmonary hypertension after mechanical circulatory support. / Tedford, Ryan J.; Hemnes, Anna R.; Russell, Stuart D.; Wittstein, Ilan S; Mahmud, Mobusher; Zaiman, Ari L.; Mathai, Stephen; Thiemann, David Ross; Hassoun, Paul M; Girgis, Reda E.; Orens, Jonathan B; Shah, Ashish S.; Yuh, David; Conte, John V.; Champion, Hunter C.

In: Circulation: Heart Failure, Vol. 1, No. 4, 11.2008, p. 213-219.

Research output: Contribution to journalArticle

Tedford, RJ, Hemnes, AR, Russell, SD, Wittstein, IS, Mahmud, M, Zaiman, AL, Mathai, S, Thiemann, DR, Hassoun, PM, Girgis, RE, Orens, JB, Shah, AS, Yuh, D, Conte, JV & Champion, HC 2008, 'PDE5A inhibitor treatment of persistent pulmonary hypertension after mechanical circulatory support.', Circulation: Heart Failure, vol. 1, no. 4, pp. 213-219.
Tedford, Ryan J. ; Hemnes, Anna R. ; Russell, Stuart D. ; Wittstein, Ilan S ; Mahmud, Mobusher ; Zaiman, Ari L. ; Mathai, Stephen ; Thiemann, David Ross ; Hassoun, Paul M ; Girgis, Reda E. ; Orens, Jonathan B ; Shah, Ashish S. ; Yuh, David ; Conte, John V. ; Champion, Hunter C. / PDE5A inhibitor treatment of persistent pulmonary hypertension after mechanical circulatory support. In: Circulation: Heart Failure. 2008 ; Vol. 1, No. 4. pp. 213-219.
@article{d4cae46470924fbbabdc4c74f0bbe06f,
title = "PDE5A inhibitor treatment of persistent pulmonary hypertension after mechanical circulatory support.",
abstract = "Pulmonary hypertension (PH) secondary to left heart failure portends a poor prognosis and is a relative contraindication to heart transplantation at many centers. We tested the hypothesis that when PH persists after adequate left ventricle unloading via recent left ventricular assist device (LVAD) therapy, phosphodiesterase type 5A inhibition would decrease PH in this population. We performed an open-label clinical trial using control patients not receiving therapy. Between 1999 and 2007, 138 consecutive patients undergoing cardiac transplantation evaluation with advanced left ventricular dysfunction, an elevated pulmonary capillary wedge pressure, and PH (defined by a pulmonary vascular resistance (PVR) >3 Woods Units), were treated with LVAD therapy. Fifty-eight of these patients reduced their pulmonary capillary wedge pressure to a value",
author = "Tedford, {Ryan J.} and Hemnes, {Anna R.} and Russell, {Stuart D.} and Wittstein, {Ilan S} and Mobusher Mahmud and Zaiman, {Ari L.} and Stephen Mathai and Thiemann, {David Ross} and Hassoun, {Paul M} and Girgis, {Reda E.} and Orens, {Jonathan B} and Shah, {Ashish S.} and David Yuh and Conte, {John V.} and Champion, {Hunter C.}",
year = "2008",
month = "11",
language = "English (US)",
volume = "1",
pages = "213--219",
journal = "Circulation: Heart Failure",
issn = "1941-3297",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - PDE5A inhibitor treatment of persistent pulmonary hypertension after mechanical circulatory support.

AU - Tedford, Ryan J.

AU - Hemnes, Anna R.

AU - Russell, Stuart D.

AU - Wittstein, Ilan S

AU - Mahmud, Mobusher

AU - Zaiman, Ari L.

AU - Mathai, Stephen

AU - Thiemann, David Ross

AU - Hassoun, Paul M

AU - Girgis, Reda E.

AU - Orens, Jonathan B

AU - Shah, Ashish S.

AU - Yuh, David

AU - Conte, John V.

AU - Champion, Hunter C.

PY - 2008/11

Y1 - 2008/11

N2 - Pulmonary hypertension (PH) secondary to left heart failure portends a poor prognosis and is a relative contraindication to heart transplantation at many centers. We tested the hypothesis that when PH persists after adequate left ventricle unloading via recent left ventricular assist device (LVAD) therapy, phosphodiesterase type 5A inhibition would decrease PH in this population. We performed an open-label clinical trial using control patients not receiving therapy. Between 1999 and 2007, 138 consecutive patients undergoing cardiac transplantation evaluation with advanced left ventricular dysfunction, an elevated pulmonary capillary wedge pressure, and PH (defined by a pulmonary vascular resistance (PVR) >3 Woods Units), were treated with LVAD therapy. Fifty-eight of these patients reduced their pulmonary capillary wedge pressure to a value

AB - Pulmonary hypertension (PH) secondary to left heart failure portends a poor prognosis and is a relative contraindication to heart transplantation at many centers. We tested the hypothesis that when PH persists after adequate left ventricle unloading via recent left ventricular assist device (LVAD) therapy, phosphodiesterase type 5A inhibition would decrease PH in this population. We performed an open-label clinical trial using control patients not receiving therapy. Between 1999 and 2007, 138 consecutive patients undergoing cardiac transplantation evaluation with advanced left ventricular dysfunction, an elevated pulmonary capillary wedge pressure, and PH (defined by a pulmonary vascular resistance (PVR) >3 Woods Units), were treated with LVAD therapy. Fifty-eight of these patients reduced their pulmonary capillary wedge pressure to a value

UR - http://www.scopus.com/inward/record.url?scp=70449381686&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70449381686&partnerID=8YFLogxK

M3 - Article

VL - 1

SP - 213

EP - 219

JO - Circulation: Heart Failure

JF - Circulation: Heart Failure

SN - 1941-3297

IS - 4

ER -